Top Health Tech Companies in Melbourne (61)
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is described as sizable and growing rapidly, with independent reporting and credit analyses pointing to continued double‑digit expansion. ARR and ACV are characterized as increasing consistently since 2022.
Customer Loyalty & Retention: Retention is depicted as very high, with consistent expansion within existing accounts that supports sustained recurring revenue growth. Commentary highlights strong share‑of‑wallet gains and durable renewals across healthcare customers.
Product Line Growth: The portfolio has broadened through repeated acquisitions (e.g., SecureLink, Verosint) and new capabilities such as passwordless authentication and agentic identity management. These moves signal active investment to expand addressable use cases and deepen the platform.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
MedHealth is a purpose-built collection of industry-leading health, medical, and employment brands that leverage diverse capabilities to deliver optimal health and employment outcomes for the people and communities they support.
MedHealth's Top Stability & Growth Strengths
Market Expansion: Active acquisitions and site growth are expanding national reach, with integrations across NDIS and allied health and operations spanning hundreds of locations. This pattern indicates continued scaling of footprint across Australia.
Strong Market Position & Advantage: Extensive scale across 300+ locations and thousands of professionals, combined with a portfolio of specialized brands, underpins a prominent position in integrated health and employment services. Alignment with ExamWorks’ international network further reinforces this standing.
Diversified Revenue Streams: Services span workplace health management, independent medical assessments, rehabilitation and return-to-work programs, employment services, NDIS support, and health technology. This breadth points to multiple income lines across both government and private sectors.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with...
Stryker's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double-digit annual sales expansion through 2025, with management guiding to continued organic growth into 2026.
Strong Market Position & Advantage: Evidence highlights leadership in orthopedic robotics and top-tier standings among global medtech peers, with notable share in joint replacement and integrated OR technologies.
Diversified Revenue Streams: Multiple segments and recent vascular-focused acquisitions broaden growth drivers and reduce reliance on any single category.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed...
St Vincent's Health Australia is Australia's largest not-for-profit provider of health and aged care services, operating public and private hospitals, residential aged care, and community and virtual care programs.
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to...
Moderna's Top Stability & Growth Strengths
Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.
Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.
Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.
The Walter and Eliza Hall Institute of Medical Research (WEHI) is a medical research institute dedicated to improving health outcomes through discovery, translation, and education. WEHI focuses on developing treatments for cancer, immune disorders, infections, and diseases of development and ageing, collaborating to make life-changing scientific discoveries that help people live healthier, longer lives.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
Lenexa Medical is an Australian-based MedTech company that has developed the LenexaCARE technology to empower clinicians to deliver targeted, long-term solutions for personalised pressure injury prevention and patient monitoring. Pressure injuries are mostly preventable, however affect millions of people globally each year whilst costing healthcare systems billions of dollars worldwide. In 2020, Australian public hospitals spent over $9 billion to...
PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists...
Intelerad is a leader enterprise workflow and medical image archiving solutions for all types of healthcare organizations. Renowned for their innovative features and functionality, Intelerad solutions, such as InteleViewer™ and InteleOne® XE, increase productivity and streamline workflow by overcoming technical barriers in distributed and complex environments. Highly scalable, flexible and robust, Intelerad’s solutions offer high performance and industry leading customer...
Montu is the leading medical cannabis company committed to improve the lives of millions of patients.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Palla Pharma Limited is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform....
Sagility is a technology-led healthcare operations and business process optimization partner serving payers and providers. It combines healthcare expertise with artificial intelligence, intelligent automation, analytics, cloud platforms, consulting, and BPaaS to streamline claims, membership, clinical, payment-integrity, provider-network, and revenue-cycle workflows across the healthcare ecosystem. Its goal is to reduce administrative costs, improve member and provider experiences, and support better clinical...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
ProPharma's Top Stability & Growth Strengths
Market Expansion: Feedback suggests the company is broadening its global footprint, including opening a new office in Hyderabad and expanding across Central and Eastern Europe via acquisitions. These moves indicate a focus on scaling operations and accessing new markets.
Strategic Partnerships: Feedback suggests targeted acquisitions such as Clinres Farmacija and Digital Lab Consulting are used to enhance capabilities and geographic reach. These integrations appear to strengthen end-to-end service coverage across regulatory, clinical, and R&D functions.
Strong Brand Reputation: Feedback suggests multiple industry awards and recognitions, including CPHI and CRO Leadership distinctions, bolster standing as a top-tier provider. External analyst mentions, such as Everest Group’s PEAK Matrix designation, reinforce credibility.
